Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) is expected to release its earnings data before the market opens on Wednesday, March 5th. Analysts expect Oramed Pharmaceuticals to post earnings of ($0.02) per share for the quarter.
Oramed Pharmaceuticals Stock Performance
Shares of NASDAQ:ORMP traded down $0.01 during trading on Friday, hitting $2.09. The company's stock had a trading volume of 58,677 shares, compared to its average volume of 323,366. The business has a 50 day moving average price of $2.31 and a two-hundred day moving average price of $2.36. The company has a market capitalization of $84.25 million, a PE ratio of 19.00 and a beta of 1.66. Oramed Pharmaceuticals has a fifty-two week low of $2.00 and a fifty-two week high of $3.48.
Analyst Upgrades and Downgrades
Separately, StockNews.com downgraded shares of Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Wednesday, February 19th.
Check Out Our Latest Stock Report on ORMP
Oramed Pharmaceuticals Company Profile
(
Get Free Report)
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.
Featured Articles
Before you consider Oramed Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oramed Pharmaceuticals wasn't on the list.
While Oramed Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
